TABLES:
Table I – Demographic and clinical characteristics of severe asthmatics with COVID-19.
AD: atopic dermatitis; ALB: albuterol; AMC: amoxicillin/clavulanate; AR: allergic rhinitis; AZM: azithromycin; BENRA: benralizumab; BX: bronchiectasis; Cax: ceftriaxone; CIP: ciprofloxacin; CRSsNP: chronic rhinosinusits without nasal polyps; CRSwNP: chronic rhinosinusitis with nasal polyps; CVD: cardiovascular diseases; GERD: gastroesophageal reflux disease; HCQ: hydroxychloroquine; HTN: hypertension; IBP: ibuprofen; ICS/LABA: Inhaled corticosteroids/Long-acting beta2-agonists; LAMA: long-acting muscarinic agents; LMWH: low molecular weight heparins; LPV/r: lopinavir/ritonavir; LTRA: leukotriene receptor antagonists; LVX: levofloxacin; MDD: major depressive disorder; MEPO: mepolizumab; MV: mechanical ventilation; NIDDM: non-insulin-dependent diabetes mellitus; NIV: non invasive ventilation; OCS: oral corticosteroids; OMA: omalizumab; PCM: paracetamol; ;TMP-SMX: trimethoprim/sulfamethoxazole; TOZ: tocilizumab